Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday

Cathie Wood/ARK Invest added to Space Exploration Technologies (SPCX) and expanded stakes in Generate Biomedicines (GENB) and Bullish (BLSH), all newly public within the past year. The key near-term catalyst cited is SpaceX joining the Nasdaq-100 on Tuesday, which could trigger passive index-tracking fund inflows, while the article frames upside potential alongside valuation risk (SpaceX ~19% above its $135 IPO but ~30% below its early peak; priced at >100x trailing revenue). For Bullish, the news highlights a $4.2B cash-and-stock deal for Equiniti amid a ~72% post-IPO drawdown and a 35% drop in digital asset sales in the latest quarter.

Analysis

The near-term edge is mostly mechanical, not fundamental. The index inclusion creates a temporary buyer that can matter for a stock with limited float and high narrative ownership, but that flow is usually strongest pre/post effective date and then fades; once passive demand is digested, the valuation has to stand on growth alone. For a company priced for years of execution, the bigger risk is not the first leg up — it is a volatility air-pocket if forward revenue or launch cadence slips even modestly.

BLSH looks like the weakest setup because its core revenue is still a high-beta proxy for crypto activity, while the acquisition-heavy strategy adds integration risk exactly when its underlying franchise is least healthy. That combination often produces lower-quality growth: headline revenue may stabilize, but margin dilution and balance-sheet complexity can keep the multiple compressed versus cleaner crypto proxies. If digital-asset volumes don’t recover, the market is likely to treat this as a financing/structural story rather than a cyclical rebound.

GENB is the opposite: long-dated optionality with real binary risk. The market is being asked to underwrite platform value before clinical de-risking, so the stock should trade more like a funding vehicle than a near-term operating company until late-stage data arrives. The contrarian read is that the AI-drug-discovery premium is already embedded in many pre-commercial names; without a clear efficacy readout, these names can drift lower as the patience window shortens.

Key Decisions for Investors

• Long SPCX only as a short-duration inclusion trade for 1-3 weeks; scale out after passive-buying flows are absorbed. Theses is falsified if the stock loses the post-inclusion range and cannot hold it on rising volume.
• Avoid chasing BLSH here; if anything, use it as a short against stronger crypto-beta names when available. The short works best over 1-3 months if crypto trading volumes remain weak and the company leans harder on acquisitions.
• Do not add to GENB ahead of clear clinical catalysts; treat it as a watchlist name until late-stage asthma data or financing terms improve visibility. Best risk/reward is a small starter only on a post-event pullback, not into optimism.
• If forced into a pair, prefer long SPCX / short BLSH as a relative-quality expression: one has a mechanical near-term buyer and secular growth, the other needs a crypto upcycle to justify the story. Fails if crypto volumes reaccelerate materially and inclusion flows disappoint.